These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 24930644)

  • 1. Propensity score-matched lesion-based comparison of mid-term angiographic outcomes of TAXUS Liberté with Cypher Bx Velocity stents for de novo native coronary stenosis and in patients with diabetes.
    Suzuki T; Ishikawa T; Nakano Y; Hino S; Mutoh M
    Intern Med; 2014; 53(12):1265-73. PubMed ID: 24930644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Propensity score matched lesion-based comparison of long-term clinical and angiographic outcomes after placement of sirolimus (Cypher Bx Velocity) and paclitaxel (TAXUS Express)-eluting stents for de novo native coronary stenosis.
    Nakano Y; Ishikawa T; Hino S; Mutoh M
    Cardiovasc Interv Ther; 2014 Apr; 29(2):93-101. PubMed ID: 24122399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospective comparison of midterm clinical and angiographic outcomes after the implantation of paclitaxel- and sirolimus-eluting stents for de novo coronary complex lesions in nonrandomized Japanese patients.
    Ishikawa T; Nakano Y; Mutoh M
    Intern Med; 2012; 51(19):2695-701. PubMed ID: 23037458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Propensity-matched lesion-based comparison of midterm outcomes of TAXUS Express and TAXUS Liberté stents for de novo native coronary stenosis.
    Ishikawa T; Nakano Y; Hino S; Suzuki T; Murakami A; Tsutsumi J; Miyamoto T; Mutoh M
    J Cardiol; 2013 Nov; 62(5):289-95. PubMed ID: 23806548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Propensity-Score Matched Comparison of Midterm Angiographic Outcomes of Sirolimus- Versus Everolimus- and Biolimus-Eluting Stents for De Novo Coronary Stenosis.
    Suzuki K; Ishikawa T; Mutoh M; Sakamoto H; Mori C; Ogawa T; Hashimoto K; Kubota T; Komukai K; Yoshimura M;
    Int Heart J; 2017 May; 58(3):320-327. PubMed ID: 28484124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and angiographic outcomes in diabetics from the ENDEAVOR IV trial: randomized comparison of zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease.
    Kirtane AJ; Patel R; O'Shaughnessy C; Overlie P; McLaurin B; Solomon S; Mauri L; Fitzgerald P; Popma JJ; Kandzari DE; Leon MB
    JACC Cardiovasc Interv; 2009 Oct; 2(10):967-76. PubMed ID: 19850257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term angiographic outcomes of sirolimus- and paclitaxel-eluting stent placement in diabetes, long lesions, and small vessels.
    Nakano Y; Ishikawa T; Mutoh M
    Cardiovasc Interv Ther; 2015 Oct; 30(4):327-37. PubMed ID: 25673511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term clinical and angiographic outcomes after sirolimus- and paclitaxel-eluting stent placement following rotablation for severely calcified lesions: a retrospective nonrandomized study.
    Tsutsumi J; Ishikawa T; Nakano Y; Yoshimura M; Mutoh M
    Cardiovasc Interv Ther; 2015 Jan; 30(1):29-37. PubMed ID: 25069959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Midterm angiographic outcomes with sirolimus- and everolimus-eluting stents for small vessels in diabetic patients: propensity-score-matched comparisons in three different vessel diameters.
    Suzuki K; Ishikawa T; Mutoh M; Sakamoto H; Kubota T; Ogawa T; Mori C; Hashimoto K; Komukai K; Yoshimura M;
    Cardiovasc Interv Ther; 2018 Jul; 33(3):205-216. PubMed ID: 28349417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective comparison of the clinical and angiographic outcomes of the sirolimus-eluting stent and the bare-metal stent in 2031 nonrandomized consecutive de novo native coronary lesions.
    Kubota T; Ishikawa T; Mutoh M
    Intern Med; 2011; 50(21):2463-70. PubMed ID: 22041343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the sirolimus-eluting versus paclitaxel-eluting coronary stent in patients with diabetes mellitus: the diabetes and drug-eluting stent (DiabeDES) randomized angiography trial.
    Maeng M; Jensen LO; Galloe AM; Thayssen P; Christiansen EH; Hansen KN; Helqvist S; Botker HE; Lassen JF; Thuesen L
    Am J Cardiol; 2009 Feb; 103(3):345-9. PubMed ID: 19166687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of post-intervention minimal stent area on 9-month follow-up patency of paclitaxel-eluting stents: an integrated intravascular ultrasound analysis from the TAXUS IV, V, and VI and TAXUS ATLAS Workhorse, Long Lesion, and Direct Stent Trials.
    Doi H; Maehara A; Mintz GS; Yu A; Wang H; Mandinov L; Popma JJ; Ellis SG; Grube E; Dawkins KD; Weissman NJ; Turco MA; Ormiston JA; Stone GW
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1269-75. PubMed ID: 20129555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two-year follow-up of the NEVO ResElution-I(NEVO RES-I) trial: a randomised, multicentre comparison of the NEVO sirolimus-eluting coronary stent with the TAXUS Liberté paclitaxel-eluting stent in de novo native coronary artery lesions.
    Abizaid A; Ormiston JA; Fajadet J; Mauri L; Schofer J; Verheye S; Dens J; Thuesen L; Macours N; Qureshi AC; Spaulding C;
    EuroIntervention; 2013 Oct; 9(6):721-9. PubMed ID: 23518218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Paclitaxel-eluting versus sirolimus-eluting stents on coronary restenosis in Korean diabetic patients.
    Kim MH; Hong SJ; Cha KS; Park HS; Chae SC; Hur SH; Gwon HC; Bae JH; Lim DS
    J Interv Cardiol; 2008 Jun; 21(3):225-31. PubMed ID: 18341520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zotarolimus- and paclitaxel-eluting stents in an all-comer population in China: the RESOLUTE China randomized controlled trial.
    Xu B; Yang Y; Yuan Z; Du Z; Wong SC; Généreux P; Lu S;
    JACC Cardiovasc Interv; 2013 Jul; 6(7):664-70. PubMed ID: 23523240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. One-year results of the CRISTAL Trial, a randomized comparison of cypher sirolimus-eluting coronary stents versus balloon angioplasty for restenosis of drug-eluting stents.
    Chevalier B; Moulichon R; Teiger E; Brunel P; Metzger JP; Pansieri M; Carrie D; Stoll HP; Wittebols K; Spaulding C; Fajadet J;
    J Interv Cardiol; 2012 Dec; 25(6):586-95. PubMed ID: 22994863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 10-month angiographic and 4-year clinical outcome of everolimus-eluting versus sirolimus-eluting coronary stents in patients with diabetes mellitus (the DiabeDES IV randomized angiography trial).
    Maeng M; Baranauskas A; Christiansen EH; Kaltoft A; Holm NR; Krusell LR; Ravkilde J; Tilsted HH; Thayssen P; Jensen LO
    Catheter Cardiovasc Interv; 2015 Dec; 86(7):1161-7. PubMed ID: 25640050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Very long-term clinical and angiographic outcomes after sirolimus- and paclitaxel-eluting stent placement for ST-elevation myocardial infarction: a propensity score-matched comparison.
    Miyamoto T; Ishikawa T; Nakano Y; Mutoh M
    Cardiovasc Interv Ther; 2017 Jan; 32(1):24-35. PubMed ID: 26979599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized comparison of a polymer-free sirolimus-eluting stent versus a polymer-based paclitaxel-eluting stent in patients with diabetes mellitus: the LIPSIA Yukon trial.
    Desch S; Schloma D; Möbius-Winkler S; Erbs S; Gielen S; Linke A; Yu J; Lauer B; Kleinertz K; Dänschel W; Schuler G; Thiele H
    JACC Cardiovasc Interv; 2011 Apr; 4(4):452-9. PubMed ID: 21511226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized comparison of sirolimus- versus Paclitaxel-eluting stent implantation in patients with diabetes mellitus.
    Lee SW; Park SW; Kim YH; Yun SC; Park DW; Lee CW; Hong MK; Rhee KS; Chae JK; Ko JK; Park JH; Lee JH; Choi SW; Jeong JO; Seong IW; Cho YH; Lee NH; Kim JH; Chun KJ; Kim HS; Park SJ
    J Am Coll Cardiol; 2008 Aug; 52(9):727-33. PubMed ID: 18718419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.